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Lentiviral vectors are attractive tools for liver-directed gene therapy because of their
capacity for stable gene expression and the lack of preexisting immunity in most human
subjects. However, the use of integrating vectors may raise some concerns about the poten-
tial risk of insertional mutagenesis. Here we investigated liver gene transfer by integrase-
defective lentiviral vectors (IDLVs) containing an inactivating mutation in the integrase
(D64V). Hepatocyte-targeted expression using IDLVs resulted in the sustained and robust
induction of immune tolerance to both intracellular and secreted proteins, despite the
reduced transgene expression levels in comparison with their integrase-competent vector
counterparts. IDLV-mediated and hepatocyte-targeted coagulation factor IX (FIX) expres-
sion prevented the induction of neutralizing antibodies to FIX even after antigen rechallenge
in hemophilia B mice and accounted for relatively prolonged therapeutic FIX expression lev-
els. Upon the delivery of intracellular model antigens, hepatocyte-targeted IDLVs induced
transgene-speciﬁc regulatory T cells that contributed to the observed immune tolerance.
Deep sequencing of IDLV-transduced livers showed only rare genomic integrations that had
no preference for gene coding regions and occurred mostly by a mechanism inconsistent
with residual integrase activity. Conclusion: IDLVs provide an attractive platform for the tol-
erogenic expression of intracellular or secreted proteins in the liver with a substantially
reduced risk of insertional mutagenesis. (HEPATOLOGY 2011;53:1696-1707)
L
iver-directed gene therapy has the potential to
treat metabolic diseases and plasma protein deﬁ-
ciencies, including hemophilia.
1-3 Moreover, he-
patic gene transfer can favor the induction of immune
tolerance, so it may also be considered for the preven-
tion or treatment of autoimmune diseases.
4,5 Because
there is no need to overcome preexisting cellular or
humoral immunity to viral vector components, the use
Abbreviations: Ag, antigen; aPTT, activated partial thromboplastin time; CTL, cytotoxic T lymphocyte; ET, enhanced transthyretin; FACS, ﬂuorescence-activated
cell sorting; FIX, coagulation factor IX; FOXP3, forkhead box P3; c-chain, cytokine receptor common subunit gamma; Gag, group-speciﬁc antigen; GFP, green
ﬂuorescent protein; HIV, human immunodeﬁciency virus; ICLV, integrase-competent lentiviral vector; IDLV, integrase-defective lentiviral vector; IFA, incomplete
Freund adjuvant; IFN, interferon; IS, integration site; LAM-PCR, linear ampliﬁcation–mediated polymerase chain reaction; LTR, long terminal repeat; LV,
lentiviral vector; MFI, mean ﬂuorescence intensity; miR-142, microRNA 142; MOI, multiplicity of infection; ns, not signiﬁcant; OVA, ovalbumin; PCR,
polymerase chain reaction; PGK, phosphoglycerokinase; PHX, partial hepatectomy; Rag2, recombination activating gene 2; Treg, regulatory T cell; UNT, untreated;
UTR, untranslated region; VCN, vector copy number.
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1696of lentiviral vectors (LVs) represents a promising
approach for liver gene transfer and immune tolerance
induction.
6-8
In previous studies, we showed that immune toler-
ance induction with LVs is dependent on stringent tar-
geting of transgene expression to hepatocytes, which
can be achieved by a combination of transcriptional
and posttranscriptional microRNA-based regulation.
6,8
Transcriptional control elements derived from hepato-
cyte-speciﬁc genes were incorporated into the vector
design to preferentially express the transgene in hepa-
tocytes. Because LVs readily transduce professional
antigen-presenting cells,
9 target sequences for a hema-
topoietic-speciﬁc microRNA—microRNA 142 (miR-
142)–were incorporated downstream of the transgene
to suppress any residual expression in antigen-present-
ing cells.
7 This stringent regulation suppressed the
induction of immunity against the transgene product
in the injected mice and induced antigen-speciﬁc
immunological tolerance, which could not be reversed
by vaccination.
6 Using this strategy, we also obtained
long-term coagulation factor IX (FIX) expression in
hemophilia B mice, which resulted in immune toler-
ance to FIX and correction of the disease phenotype.
8
Although these studies have demonstrated the feasi-
bility of gene replacement therapy and immune toler-
ance induction with LVs, concerns remain about the
potential long-term adverse effects of vector integration
due to insertional mutagenesis. Although advanced LV
design potentially reduces this risk,
10,11 the impact of
LV integration in the liver is largely unexplored. More-
over, it is not known whether the tolerogenic outcome
of microRNA-regulated LV delivery depends on
sustained high levels of transgene expression within
hepatocytes, which requires substantial levels of LV
integration and would limit the application of this
ﬁnding outside gene replacement strategies for the cor-
rection of monogenic diseases.
Integrase-defective lentiviral vectors (IDLVs) are
typically generated by the packaging of the vector
with catalytically inactive human immunodeﬁciency
virus (HIV) integrase.
12,13 The class I D64V muta-
tion in the integrase catalytic site substantially
reduces integration (10
2-t o1 0
3-fold) without com-
promising other steps in the transduction pathway
and was thus adopted for this study.
12,14-18 Upon
transduction, IDLVs can support transgene expres-
sion from the nonintegrated proviral forms. Because
this episomal DNA is progressively lost in actively
dividing cells, transgene expression is only tran-
sient.
14,15,19 In contrast, IDLVs have been reported
to support sustained transgene expression in quiescent
mouse tissues, such as the retina and central nervous
system, likely because the episomal vector DNA is
retained within the postmitotic nucleus.
17,18,20 Despite
these advances, the ability of IDLVs to achieve thera-
peutically meaningful transgene expression after he-
patic gene delivery and to induce immune tolerance
has never been studied. Moreover, the nature of any
persistent IDLV genome in transduced cells is poorly
deﬁned because a comprehensive characterization of
the residual IDLV integration proﬁle is lacking. This
study addresses all these outstanding questions and
provides evidence supporting IDLVs as an emerging
platform technology for liver gene transfer and
immune tolerance induction.
Materials and Methods
Vector Construction. Plasmids pCCLsin.cPPT.ET.
cFIX.142T, pCCLsin.cPPT.PGK.OVA, and pCC
Lsin.cPPT.ET.OVA.142T (ET ¼ enhanced transthy-
retin, OVA ¼ ovalbumin, and PGK ¼ phosphoglycer-
okinase) were constructed with standard cloning
techniques. Details are available upon request.
Mouse Experiments. Green ﬂuorescent protein
(GFP)–expressing integrase-competent lentiviral vectors
(ICLVs) and IDLVs were administered to 7-week-old
female BALB/c mice by tail vein injection. Six-week-
old female and male C57BL/6 FIX-knockout mice
were injected intravenously on 2 consecutive days with
a total p24 dose of 260 lg( 2  500 lL) in FIX-
expressing ICLVs or IDLVs supplemented with 40
mg/mL polybrene. For 70% partial hepatectomy, mice
were anesthetized with isoﬂurane. Liver sections were
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DNA extraction kit, Qiagen, Belgium). FIX activity in
citrated plasma was quantiﬁed (Biophen factor IX
chromogenic activity assay, Hyphen Biomed, France)
according to the manufacturer’s instructions with
normal dog plasma as a reference (detection limit
> 0.1%). All animal experiments were approved by
the Animal Ethics Committee of the University of
Leuven or the San Raffaele Institutional Animal Care
and Use Committee (321).
Integration Site (IS) Analysis. To analyze ICLV
and IDLV integration, we used standard and nonres-
trictive, 50-long terminal repeat (50-LTR)–mediated
and 30-LTR–mediated linear ampliﬁcation–mediated
polymerase chain reaction (LAM-PCR) as previously
described.
21,22
Further details can be found in the Supporting
Information.
Results
IDLVs Efﬁciently Transfer Episomal Genomes Into
Human Hepatocytes In Vitro but Drive Lower
Levels of Transgene Expression Than Their Integra-
tion-Competent Counterparts. We generated GFP-
expressing LVs with either integrase-defective (IDLV) or
integrase-competent (ICLV) packaging constructs and
compared their transduction efﬁciency and transgene
expression levels in human cell lines and primary hepa-
tocytes in vitro. To drive transgene expression, we used a
hepatocyte-speciﬁc chimeric promoter (designated as
ET).
8 The vectors carried target sequences for miR-142
in the transgene 30-untranslated region (30-UTR;
ET.GFP.142T; Fig. 1A). The physical particle content
was determined by HIV-1 group-speciﬁc antigen (Gag)
p24 quantiﬁcation. To determine infectivity, which we
deﬁned as transducing units per physical particle, we
designed an ad hoc quantitative polymerase chain
Fig. 1. IDLV performance in hepatocytes culture (A) Schematic representation of the third-generation self-inactivating vector used for these
studies. SD: splicing donor site. SA: splicing acceptor site. w: packaging signal (including 5’ portion of GAG gene (GA)). RRE: Rev responsive
element. cPPT: central polypurine tract. Wpre: woodchuck hepatitis virus post-regulatory elements. 142T: miR-142 target sequence made of 4
tandem copies of a sequence perfectly complementary to miR-142. Vectors were produced with integrase-competent (ICLV) or integrase-defective
(IDLV) construct. The green ﬂuorescent protein (GFP), coagulation Factor IX (FIX) and ovalbumin (OVA) were driven from the hepatocyte-speciﬁc
ET promoter composed of synthetic hepatocyte-speciﬁc enhancers and transthyretin promoter or the ubiquitously expressed phosphoglycerokinase
(PGK) promoter (B) Percentage of GFP
þ cells and mean ﬂuorescence intensity of GFP (MFI; left axis) and vector copies/diploid genome (vector
copy number – VCN; right axis) in Huh7 cells transduced with ICLV or IDLV at the indicated multiplicity of infection (MOI) and analyzed 3 days or
2 weeks after transduction by ﬂow cytometry. Black bars correspond to ICLV-transduced cells, grey bars to IDLV-transduced cells. Circles show
VCN. The results are presented as mean 6 standard error of the mean (SEM; n ¼ 3). (C) Representative images of human primary hepatocytes
transduced as indicated or left untreated (UNT) and analyzed by live ﬂuorescence microscopy 1 week after transduction. Nuclei are stained with
Hoechst. (D) Percentage of GFP
þ cells and MFI of GFP (5 ﬁelds per sample; left axis) and VCN (circles, right axis) in cultures from quiescent
human primary hepatocytes. The results are presented as mean 6 range (n ¼ 2). Abbreviations: MOI, multiplicity of infection; UNT, untreated.
1698 MA ´TRAI ET AL. HEPATOLOGY, May 2011reaction (PCR) that selectively ampliﬁed the reverse-
transcribed vector genome and discriminated it from
plasmid DNA, which was carried over from the transfec-
tion used to produce the vectors (Supporting Informa-
tion Fig. 1). IDLVs and ICLVs had similar infectivity in
several human cell lines (Supporting Information Table
1 and data not shown). We transduced the hepatocyte
Huh7 cell line and measured vector genomes and GFP
expression at 3 days and 2 weeks post-transduction (Fig.
1B). Initially, comparable amounts of reverse-transcribed
vectors were present in IDLV- and ICLV-transduced cells.
However, the frequency of GFP
þ cells and the mean ﬂuo-
rescent intensity (MFI) of GFP were lower in IDLV-trans-
duced cells versus ICLV-transduced cells (P < 0.01, n ¼
3), and this indicated less efﬁcient expression from the for-
mer vector. Analysis of the same cultures 2 weeks after
transduction showed a nearly complete loss of vector
genomes and GFP
þ cells in the IDLV-transduced cells, as
expected for an episomal form.
We then tested the same vectors on human primary
hepatocytes, which do not proliferate in culture, and
showed that IDLVs attained similar levels of transduced
vector genomes vector copy number (VCN) 1 week after
transduction but expressed GFP at substantially lower
levels in comparison with matched doses of ICLVs (n ¼
2; Fig. 1C,D). Overall, these data indicate that IDLVs
efﬁciently transfer episomal vector genomes into hepato-
cytes. However, these forms provide a less proﬁcient sub-
strate for the transcriptional machinery than the inte-
grated proviral vectors.
IDLVs Support FIX Expression From Hepatocytes
in Mice. To ascertain that IDLVs could be used to
transduce hepatocytes in vivo, we injected increasing
doses (5-, 20-, and 40-lg HIV-1 Gag p24 equivalents,
n ¼ 8) of GFP-expressing IDLVs (ET.GFP.142T)
intravenously into adult mice and measured GFP
expression in hepatocytes and vector DNA contents in
the liver 5 weeks post-injection (Fig. 2A). A vector
dose–dependent increase in hepatic transduction was
apparent; the yield of GFP
þ hepatocytes in the treated
livers was as high as 13% according to an analysis by
GFP-speciﬁc immunostaining. Subsequently, we
administered matched doses (20-lg HIV-1 Gag p24
equivalents) of GFP-expressing IDLVs and ICLVs
(ET.GFP.142T) intravenously to adult mice (n ¼ 20
for IDLV mice and n ¼ 4 for ICLV mice in three in-
dependent experiments) and measured GFP expression
and vector DNA contents in the liver at different
times post-injection (Fig. 2B,C). One week post-injec-
tion, GFP-expressing hepatocytes were readily detecta-
ble in IDLV-treated mice, although the frequency and
the intensity were substantially lower than those
Fig. 2. IDLV performance in the mouse liver (A) Morphometric analysis of GFP-expressing hepatocytes and VCN in the liver of mice injected
with the indicated HIV-1 p24 Gag equivalents of IDLV.ET.GFP.142T and analyzed at the indicated time post-injection. GFP
þ cells were identiﬁed
either by immunostaining or direct ﬂuorescence. Results are presented as mean 6 SEM of n ¼ 3 mice per time point, 5-10 optical ﬁelds
scored from 5-10 non-consecutive GFP-immunostained (ﬁlled bars) or unstained (open bars) liver sections per mouse (left axis). Circles show
VCN (right axis), as mean 6 SEM. (B) Same analysis performed for IDLV- (grey bars) vs. ICLV- (black bars) injected mice, n ¼ 3-7 mice per
IDLV time point from 3 different experiments. (C) Representative images of unstained liver sections from mice reported in (B). Nuclei were
stained with TOPRO-3. Abbreviation: UNT, untreated.
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The contents of reverse-transcribed vector genomes
were only slightly lower in mice treated with IDLVs
versus mice treated with ICLVs and reached up to 1.5
vector copies per diploid genome. However, although
the GFP expression and the vector content remained
stable in the ICLV-treated mice, the frequency of
GFP
þ hepatocytes and the vector content progressively
decreased with increasingly longer times post-injection
for the IDLV-treated groups.
We then administered matched high doses (260-lg
HIV Gag p24 equivalents per mouse) of IDLV- or
ICLV-expressing canine FIX complementary DNA
(ET.FIX.142T) to adult hemophilia B mice (n ¼ 15
for IDLV mice and n ¼ 8 for ICLV mice; Fig. 3).
IDLV delivery resulted in prolonged production of
FIX in mouse plasma at levels considered within the
therapeutic range (up to 1.5% of normal levels). In
agreement with the different efﬁciencies of expression
observed for the GFP marker, the FIX levels supported
by IDLVs were up to 15-fold lower than those sup-
ported by the cognate ICLVs. Twelve weeks post-injec-
tion, the VCN in transduced livers was 0.22 6 0.16
per diploid genome for the IDLV group and 4.36 6
0.24 per diploid genome for the ICLV group. At this
time, some of the IDLV-treated mice (n ¼ 7) and
some of the ICLV-treated ones (n ¼ 3) were subjected
to 70% partial hepatectomy. We validated the concept
that partial hepatectomy resulted in an increased incor-
poration of bromodeoxyuridine consistent with de
novo induction of hepatocyte proliferation (data not
shown). In the recovering mice, FIX levels remained
comparable to those measured before hepatectomy in
the ICLV-treated group (Fig. 3A). In contrast,
although FIX levels in the IDLV-treated mice were rel-
atively stable before partial hepatectomy, they signiﬁ-
cantly declined shortly afterwards in the interval
between weeks 12 and 20 (P < 0.05; Fig. 3B).
Instead, there was no statistically signiﬁcant decline in
FIX expression in another IDLV-treated cohort that
was not subjected to PHX in the same time interval
(weeks 12-20). Nevertheless, FIX expression had
become subtherapeutic after 1 year (Fig. 3C).
Overall, these data indicate that IDLVs, though less
efﬁcient than their ICLV counterparts at expressing
transgenes from human and murine hepatocytes, can
support therapeutically relevant levels of transgene
expression in vivo. This ﬁnding warranted a further
assessment of the risk/beneﬁt ratio of the IDLV plat-
form. The posthepatectomy drop in FIX levels
observed in IDLV-treated mice suggested that FIX
expression could be attributed mainly to nonintegrated
vector episomes. Thus, we investigated the residual
IDLV integration frequency.
Fig. 3. Functional FIX expression in hemophilic mice FIX KO mice were injected with ICLV.ET.FIX.142T (A) or IDLV.ET. FIX.142T (B) and FIX activ-
ity was monitored in the mouse plasma collected by retro-orbital bleeding. Partial hepatectomy (PHX) was performed at week 12. In both panels,
grey lines correspond to untreated (UNT) FIX KO mice. (C) FIX activity in FIX KO mice injected with IDLV.ET.FIX.142T monitored for 1 year post
injection and not subjected to partial hepatectomy. Abbreviations: PHX, partial hepatectomy; UNT, untreated.
1700 MA ´TRAI ET AL. HEPATOLOGY, May 2011IDLVs Integrate Only to Background Levels and
With Features Incompatible With Residual Catalytic
Activity of the HIV Integrase. Because the D64V
mutation reduces LV integration by 2 to 3 log (see
also Fig. 1),
13 low-level integration still occurs with
this mutant. We therefore assessed residual IDLV inte-
gration in vitro and in the treated livers. First, two
murine cell lines were transduced with IDLV.GFP and
were subsequently cultured for 8 weeks to dilute out
the episomal forms. The GFP
þ cells were then selec-
tively enriched by ﬂuorescence-activated cell sorting
(FACS). We then applied nonrestrictive and standard,
50- and 30-LTR–mediated LAM-PCR strategies
21,22
along with 454 pyrosequencing to analyze IDLV inte-
gration in the bulk positive cell populations and in
single cell–derived clones. A comprehensive, large-scale
analysis of more than 800 unique, mappable IDLV ISs
on the mouse genome revealed close to random
genomic integration of IDLVs without any preference
for gene coding regions (Fig. 4A). In contrast, the
3317 unique ICLV ISs that could be mapped to the
genome showed the characteristic lentiviral IS proﬁle
with gene coding regions as preferred targets. To dis-
tinguish noncanonical integration from residual inte-
grase activity–mediated integration, we screened our
IDLV and ICLV integration data for the presence of
the characteristic 5-bp direct repeat of host DNA
ﬂanking the proviral terminal CA dinucleotide as a
hallmark of integrase activity. For IDLVs, we retrieved
the 50- and 30-vector–host genome junctions in 22
Fig. 4. Assessment of residual IDLV integration in vitro and in the liver (see also Supporting Figure 2-4 and Table 1) (A) Distribution of inte-
gration sites determined by LAM-PCR that were located in gene coding regions of ICLV- (black bars) or IDLV- (grey bars) transduced mouse SC-1
and C1498 cells (SC-1 cells: 533 IDLV IS, 2419 ICLV IS; C1498: 271 IDLV IS, 898 ICLV IS). (B) LTR deletions (red triangles) and genomic dele-
tions (blue triangles) identiﬁed in IDLV and ICLV integrants from which both the 5’ and 3’ genomic ﬂanking region were identiﬁed by LAM-PCR.
The terminal CA dinucleotide (underlined, GT at end of 5’ strand LTR, complementary to CA at end of 3’ strand LTR) is shown if exist. The 5 bp
direct repeat of host DNA ﬂanking the provirus is delineated in bold. The number of deleted bp in host DNA is indicated (Del.). LTR: long termi-
nal repeat. LV: lentiviral vector. B2-PCR product gel image for primer set 1 (C) and primer set 2 (D). The arrows indicate the position of the re-
spective PCR bands; densitometric analysis of the B2-PCR bands received with primer set 1 (E) and primer set 2 (F) in the untreated (UNT),
IDLV- and ICLV-treated liver samples. Statistically signiﬁcant differences (*) were found between ICLV and IDLV (t-test: P < 10
-4 and P < 10
-11)
as well as between UNT and IDLV (t-test: P < 0.002) with both primer sets 1 and 2, respectively. Abbreviation: UNT, untreated.
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considerations make it extremely unlikely that such
junctions could come from two distinct integration
events) and in 2 instances from single cell–derived
clones. Seventeen of the 24 integrants showed loss of
the CA nucleotide at least at one end of the vector. All
24 integrants revealed a partial deletion of LTR and/or
genomic sequences, and no 5-bp direct repeat could
be detected in any of these vector-genome junctions
(Fig. 4B). In contrast, 18 of 19 ICLV integrations for
which both sequence ends were mapped revealed nei-
ther CA dinucleotide deletions nor LTR sequence dele-
tions, and they harbored the typical 5-bp direct repeat
without genomic deletions. In agreement with these
data, screening for LTR sequence deletions in our
complete IS data sets showed that one-third of all
IDLV integrations had a partial loss of the LTR
sequence, whereas LTR deletions accounted for only
approximately 2% of all ICLV sequences. Interestingly,
our LAM-PCR screening for potentially broken linear
and circular vector forms, which used vector internal
primers binding to the GFP transgene or vector back-
bone, did not show any sign of integration (data not
shown). Our data provide direct molecular evidence
that the background integration of D64V IDLVs is
not mediated by residual catalytic activity of the mu-
tant integrase.
To determine the residual IDLV integration fre-
quency in the treated livers, we ﬁrst performed a
semiquantitative nested PCR to amplify host DNA–
vector junctions with short interspersed (SINE) nu-
clear B2 repeat sequences that are scattered through-
out the mouse genome (Supporting Information Fig.
2). Although the livers from ICLV-treated mice
yielded intense bands for the 50- and 30-vector–host
genome junctions, the livers from IDLV-treated mice
showed bands of much lower intensity consistent
with low-level residual integration (Fig. 4C-F). We
further retrieved vector sequences from the treated
livers at 6 to 12 weeks post-injection by highly sensi-
tive LAM-PCR and deep sequencing. The number of
unique ISs found in the IDLV-treated liver samples
was signiﬁcantly lower than the number in the ICLV
samples. In the IDLV liver samples (n ¼ 16), a total
of 35 unique, mappable ISs could be recovered versus
785 ISs in the ICLV samples (n ¼ 4, P < 10
 9)
with an almost 100-fold lower frequency of retrieval
(Table 1). Accordingly, we retrieved an excess of 2-
LTR junctions from IDLV-treated liver samples versus
ICLV-treated ones, and this was suggestive of the
presence of episomal vector forms (2-LTR junctions:
54.5% in IDLV samples and 2.8% in ICLV samples;
Table 1 and Supporting Information Fig. 4). Consist-
ent with the in vitro IS data, the few retrieved
Table 1. Deep Sequencing of ICLV- and IDLV-Transduced Liver Samples
Vector
Raw Sequence
Reads
1-LTR Amplicon/Internal
Control
2-LTR
Amplicon
Reads With an
LTR
1,  20-nt Genomic Sequence
Unique
Mappable ISs
LTR Deleted at the
Genome Junction by >3n t
ICLV 2787 211 51 1688 152 2 (10, 11 nt)
2179 13 0 244 244 1 (22 nt)
3169 896 53 101 101
2822 250 258 288 288 2 (8, 23 nt)
IDLV 1451 284 760 340 0
971 530 237 186 2
1227 373 82 767 0
1365 466 154 26 2 1 (21 nt)
2264 371 838 841 2
2752 400 996 1322 1
1349 221 795 308 4
1173 193 587 277 3 1 (11 nt)
2809 347 1538 502 1 1 (8 nt)
1722 215 801 421 4 2 (19, 24 nt)
3494 350 2124 916 4 2 (14, 21 nt)
3260 223 2397 500 2
3291 316 1799 621 4 1 (25 nt)
2771 330 1963 232 2
2882 275 2795 318 0
3251 241 1787 808 4 1 (8 nt)
This table shows 454 sequencing results for ICLV- and IDLV-transduced liver samples. GFP-transduced samples are indicated in bold, and FIX-transduced sam-
ples are indicated in regular type. The 1-LTR amplicon and vector internal control fragments (resulting from the 30-LTR-U3 LAM-PCR primer annealing at 50-LTR-U3)
could not be distinguished by sequencing. Notably, the 2-LTR amplicon LAM-PCR product (restriction enzyme Tsp509I, AATT) exhibited a length of only 18 bp with-
out an LTR and linker sequence, and this resulted in the overrepresentation of sequenced 2-LTR amplicons versus the 1-LTR amplicon and the internal control
(Supporting Information Fig. 4).
1702 MA ´TRAI ET AL. HEPATOLOGY, May 2011integrations did not show enrichment for genes and
frequently showed deletion in the LTR ends (25.7%
in IDLV samples and 0.6% in ICLV samples; Table
1 and Supporting Information Fig. 3).
Overall, these studies indicate abrogation of the
HIV integrase–dependent integration in IDLVs. The
background integration in treated livers exhibits molec-
ular features reminiscent of those described for plas-
mids and other types of episomal DNA. This genomic
IS analysis further underscores the minimal risk of
insertional mutagenesis by IDLVs.
IDLV Delivery Can Tolerize the Recipient to
Foreign Antigens. We then investigated whether he-
patocyte-targeted expression by IDLVs induces trans-
gene-speciﬁc immunological tolerance. We monitored
liver inﬁltration by lymphocyte subpopulations after
the injection of IDLV.ET.GFP.142T or a control
IDLV expressing GFP from a constitutive PGK pro-
moter, which was expected to induce a GFP-speciﬁc
immune response
6 (n ¼ 20 for the IDLV.142T
group, n ¼ 19 for the IDLV group, and n ¼ 9 for
the untreated group). CD8
þ T cell inﬁltration was
well detected 1 week after IDLV treatment inde-
pendently of the presence or absence of miR-142
regulation. However, although the CD8
þ T cells
persisted at a high frequency in the livers of mice
treated with the unregulated vector, they decreased
substantially 3 weeks post-injection in IDLV.142T-
treated mice (Fig. 5A). These ﬁndings were paral-
leled by the induction of GFP-speciﬁc CD8
þ T cells
(Fig. 5B). The frequency of CD4
þCD25
þFOXP3
þ
regulatory T cells (Tregs; FOXP3 ¼ forkhead box
P3) increased in the liver after treatment with both
IDLV types 3 weeks after vector administration;
however, the ratio of Tregs to CD8
þ effector cells
was much higher in the mice treated with miR-142-
regulated vector than in control vector treated mice
(Fig. 5C,D).
To investigate whether active tolerance was estab-
lished, we challenged the mice by intramuscular vacci-
nation with GFP-encoding plasmids and evaluated
the frequency of GFP-speciﬁc CD8
þ T cells in the
spleen and liver (Fig. 6A,B). Although the low fre-
quency of GFP-speciﬁc CD8
þ T cells induced in the
spleens and livers of IDLV.142T-treated mice did not
increase upon rechallenge, there were many more
antigen-speciﬁc effectors in the control, unregulated
IDLV-treated mice after the primary (IDLV) and sec-
ondary challenges (intramuscular plasmid). In addi-
tion, residual levels of vector genomes and GFP
expression were still detectable in the livers of mice
previously treated with IDLV.142T after rechallenge
(Fig. 6B and data not shown).
To further conﬁrm that IDLV.142T is able to direct
the immune system toward the induction of immune
tolerance to transgene antigens, we reconstituted
immune-deﬁcient recipients through the adoptive
transfer of immune cells derived from either immu-
nized (IDLV-treated) or tolerized (IDLV.142T-treated)
mice (Fig. 6C). Rag2
 / c-chain
 /  mice (Rag2 ¼
recombination activating gene 2; c-chain ¼ cytokine
receptor common subunit gamma) were, therefore,
ﬁrst transduced with hepatocyte-targeted ICLVs
(ET.GFP.142T) to obtain robust GFP expression in
hepatocytes. A pool of splenocytes and liver lympho-
cytes derived from naive, control IDLV-treated or
IDLV.142T-treated animals was transferred 1 month
later. Although comparable amounts of GFP-
Fig. 5. Kinetics of liver lymphocytes inﬁltrate after IDLV gene transfer Mononuclear cells (MNC) were isolated from the liver of mice injected
with matched doses of hepatocyte targeted ET.GFP.142T IDLV (IDLV.142T) or control PGK.GFP IDLV (IDLV) at the indicated time post-injection
(IDLV.142T n ¼ 20, IDLV n ¼ 19, untreated n ¼ 9 in 3 indipendent experiment) (A) Frequency of CD8
þ T, (B) GFP200-208-pentamer-positive,
and (C) CD4
þCD25
þFoxp3
þ Tregs inﬁltrating cells was evaluated by ﬂow cytometry. Data are expressed as the mean % 6 SD (n ¼ 3 per group
per time point; a representative experiment out of 3 is shown). (D) Ratio of T regs to CD8þ T cell. Abbreviation: CTL, cytotoxic T lymphocyte.
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reconstituted with naive cells or cells derived from tol-
erant (IDLV.142T-treated) mice, a complete clearance
of GFP
þ hepatocytes was observed in recipient mice
reconstituted with cells derived from control, unregu-
lated IDLV-treated mice, and this was accompanied by
a loss of vector DNA. These results indicate that only
those cells derived from control mice exhibited the
full effector potential upon adoptive transfer, whereas
the effector cells derived from tolerized mice
(IDLV.142T-treated) were kept in check by the
induced regulatory compartment. Taken together,
these data indicate that GFP-speciﬁc immunological
tolerance was established.
To assess whether immune tolerance could be
induced by IDLVs toward a therapeutically relevant
secreted antigen, we evaluated the anti-FIX immune
response in hemophilic mice treated with FIX-encod-
ing IDLV.142T. Activated partial thromboplastin time
(aPTT)–based Bethesda assays showed no anti-FIX in-
hibitory activity (Fig. 6D). Importantly, when these
IDLV.142T-treated mice were challenged with FIX
protein in incomplete Freund adjuvant (IFA), they
remained negative for anti-FIX neutralizing
Fig. 6. Transgene-speciﬁc tolerance after IDLV liver gene transfer (A) Secondary immune response to the vector-encoded antigen was assessed
by frequency of IFN-c-producing, GFP-speciﬁc CD8
þ T cells in the spleen of mice subjected to antigen re-challenge (by intramuscular vaccination
with GFP-encoding plasmids) 6 weeks after IDLV treatment. Single values are plotted and the mean 6 SD number of GFP-speciﬁc CD8
þ T cells
per 10
6 total CD8
þ T cells is shown (n ¼ 6 per group). Representative wells are shown on top. (B) Quantiﬁcation of the CD8
þ GFP200-208-pen-
tamer-positive T cells inﬁltrating the liver of mice treated with the indicated IDLV (IDLV.PGK n ¼ 9; IDLV.PGK.142T n ¼ 6; IDLV.ET.142T n ¼ 3)
after antigen re-challenge. Single values are plotted and mean 6 SD is shown. Mean 6 SD VCN in the liver is indicated. (C) Morphometric anal-
ysis of GFP
þ hepatocytes and VCN in the liver of immune-deﬁcient mice previously injected with ET.GFP.142T ICLV and adoptively transferred (AT)
with cells derived from naı ¨ve, IDLV.PGK- and IDLV.ET.142T-treated mice (from 5A-C). Mean 6 SEM of n ¼ 3 mice (left axis). Circles show mean
6 SEM VCN (right axis). A representative ﬁeld is shown on top. Note that residual vector DNA in the liver of mice in which GFP-expressing hepa-
tocytes were completely cleared can be ascribed to the persistence of vector genomes in transduced macrophages and endothelial cells that did
not express GFP. (D) Plasma samples from the various groups of animals were screened for anti-FIX neutralizing antibodies using an aPTT mixing
assay using a positive control of 2.6 Bethesda Units (BU) and a known negative control. Samples were assayed in a blinded fashion. Groups
include FIX KO mice treated with the indicated ET.FIX.142T vector or untreated (UNT) 12 weeks after vector administration, with or without chal-
lenge with canine FIX and IFA. Only untreated mice receiving FIX þ IFA had detectible neutralizing anti-FIX antibodies and all were greater than
2.6 BU. Abbreviations: Ag, antigen; ns, not signiﬁcant; UNT, untreated.
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not injected with any vector but were immunized
with FIX and IFA showed the induction of neutraliz-
ing antibodies (the Bethesda titer was >2.6 Bethesda
units in these mice, whereas it was below the level of
detection in all recipient mice of the other cohorts).
These results indicate that FIX-speciﬁc immunological
tolerance was established.
IDLV Delivery Induces Antigen-Speciﬁc Tregs. To
determine whether the antigen speciﬁcity of liver-inﬁl-
trating Tregs is affected by IDLV.142T administration,
the antigen-driven conversion of naive CD4
þFOXP3
 
T cells into FOXP3
þ Tregs was evaluated. To this end,
we adoptively transferred naive CD4
þ T cells obtained
from double-transgenic mice for an OVA-speciﬁc T
cell receptor (major histocompatibility complex II–re-
stricted, OTII) and a GFP reporter knock-in down-
stream of the Foxp3 promoter. OTII CD4
þ FOXP3-GFP
Ly5.2 T cells were isolated, FACS-sorted to deplete
FOXP3
þ cells, and adoptively transferred into naive
Ly5.1 recipient mice before the injection of OVA-
encoding IDLVs or IDLV.142T (Fig. 7A). Three weeks
later, the recipient mice were euthanized, and GFP
expression, used as a surrogate marker for FOXP3, was
determined in OTII Ly5.2 CD4
þ T cells. A signiﬁ-
cantly higher frequency of OVA-speciﬁc Tregs was
detected speciﬁcally in the IDLV.142T-treated mice
versus the untreated or control, unregulated IDLV-
treated mice (Fig. 7B). These results indicate that the
pattern of OVA expression driven by miR-142–regu-
lated IDLVs in the liver favored the conversion of
transgene-speciﬁc naive CD4
þ T cells into transgene-
speciﬁc FOXP3
þ-induced Tregs (Fig. 7B,C).
Overall, these data indicate that hepatocyte-targeted
expression of foreign antigens, including intracellular
or secreted, therapeutically relevant (FIX) and model
antigens (GFP and OVA), by IDLVs can result in a
state of transgene-speciﬁc immunological tolerance due
to a strong contraction of the transgene-speciﬁc effec-
tor compartment and the induction of the transgene-
speciﬁc regulatory compartment.
Discussion
IDLVs are emerging as an attractive platform for
transgene expression for several purposes.
23 This plat-
form harnesses the pantropism and proﬁciency of LV
transduction without relying on integration and perma-
nent modiﬁcation of the cellular genome. Here we
show that IDLVs can be used to express transgenes for
Fig. 7. Induction of transgene-speciﬁc Tregs by IDLV treatment CD4
þ cells isolated from OTII Ly5.2
Foxp3-GFP transgenic mice were FACS-sorted
to remove GFP
þ cells obtaining an homogeneous population of CD4
þ non-regulatory T cells with a unique antigen speciﬁcity (OVA323-339 pre-
sented in IA
b molecule). (A) Tregs-depleted OTII CD4
þGFP
- (2.5&times;10
6/mouse) were adoptively transfer intravenously into naı ¨ve C57BL/6
Ly5.1 recipient mice one day before the injection of IDLV.PGK (n ¼ 3) or IDLV.ET.142T (n ¼ 3) encoding for OVA. Three weeks after IDLV admin-
istration livers were harvested and inﬁltrating lymphocytes isolated. OVA-speciﬁc induced Tregs (iTregs) were measured as GFP
þ cells gated on
CD4
þLy5.2
þ. (B) a representative histogram and (C) mean % induced Tregs 6 SEM is reported.
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is stringently targeted to hepatocytes with transcrip-
tional and miR-142–mediated regulation. Although the
IDLV expression efﬁciency is lower than that observed
for ICLVs, the expression levels are sufﬁcient to induce
immune tolerance and achieve prolonged therapeutic
effects in a clinically relevant disease model. Moreover,
the nonintegrating feature of the platform provides im-
portant safety advantages because of the low risk of gen-
otoxicity and the reversibility of transgene expression.
The declining transgene expression of IDLVs in pro-
liferating cells has been mostly ascribed to the progres-
sive loss of episomal DNA from the cell nucleus dur-
ing mitosis versus the stably integrated provirus of
ICLVs. Here, we have reliably quantiﬁed the contents
of reverse-transcribed vector genomes and the trans-
gene expression level in transduced dividing or quies-
cent cells, and we have shown that the expression efﬁ-
ciency per genome copy is signiﬁcantly lower for
IDLVs versus ICLVs in hepatocytes. This may be due
to diffusion of the episomes to nuclear areas that are
not involved in active transcription, inefﬁcient chroma-
tin deposition, or enrichment with histone modiﬁca-
tions typical of transcriptionally silenced chromatin.
24
This is in contrast to what has been reported in other
quiescent tissues, such as the retina and the central
nervous system, and may indicate tissue-speciﬁc factors
affecting the expression and stability of episomal
IDLVs. It is conceivable that the incorporation of
additional genomic elements into the IDLV backbone
may improve the expression proﬁciency and nuclear
stability.
We have shown that IDLV background integration
occurs by mechanisms incompatible with residual ac-
tivity of the mutant integrase because they often pres-
ent deletions in the LTR ends and lack the typical
ﬂanking genomic repeats at the insertion site. These
events may be mediated by nonhomologous end join-
ing of linear episomes to sites of chromosomal break-
age.
25 Although we cannot rule out a contribution to
the observed sustained FIX expression by these inte-
grated IDLVs, the signiﬁcant decline of FIX expression
with the induction of hepatocyte proliferation after
partial hepatectomy strongly suggests that in vivo
expression is mostly mediated by the episomal forms.
The signiﬁcantly lower expression of IDLVs versus
ICLVs represents a limiting factor for their application
to stable therapeutic gene replacement in the liver, at
least in the current design. However, IDLVs may be
considered whenever reversible gene transfer is prefera-
ble (e.g., the testing of a new gene therapy approach),
especially if the clinical setting imposes high safety
bars in the face of existing treatment options (e.g.,
hemophilia) or the biological effects of gene-based
delivery are difﬁcult to predict or may entail substan-
tial toxicity. Here we demonstrate the therapeutic
potential of inducing a prolonged window of FIX
expression in the plasma of hemophilic mice. Appa-
rently, FIX expression was more prolonged than GFP
expression after hepatic transduction with IDLVs. This
possibly reﬂects the higher vector doses and/or differ-
ences in the detection limits of the assays used to
quantify the expression of the respective transgene
products. IDLVs may also be used for hepatic expres-
sion of therapeutic proteins, such as interferon (IFN)
and other cytokines, in chronic viral hepatitis or he-
patic tumors; gene-based delivery may provide thera-
peutic concentrations of the factor at the disease site
with limited systemic exposure and only for a deﬁned
window of time.
26,27
Hepatic gene transfer has been associated with the
induction of immunological tolerance to the transgene
product with several vector platforms.
28-30 In contrast
to other viral vectors used in gene therapy, most sub-
jects are immunologically naive to the IDLV vector
components, so it is unlikely that IDLV-transduced he-
patocytes would be recognized by vector-speciﬁc cyto-
toxic T cells. Here we demonstrate a major accompa-
nying beneﬁt of hepatocyte-targeted IDLV gene
transfer: the induction of transgene-speciﬁc Tregs and
active tolerance to the transgene product. Most impor-
tantly, this response may extend beyond the duration
of vector-mediated transgene expression and improve
the efﬁcacy of existing protein replacement therapy by
preventing the induction of neutralizing antibodies,
which represent one of the major hurdles of this treat-
ment. Indeed, the in vivo induction of antigen-speciﬁc
Tregs by microRNA-regulated IDLVs may well repre-
sent their most attractive feature to date, and it
provides an intriguing contrast to the immunogenic
nature of unregulated IDLV delivery, which is cur-
rently being explored for the design of improved virus-
based vaccines.
31,32 Although IDLVs are less efﬁcient
at expressing the transgene in hepatocytes in compari-
son with their integrating counterparts, they are
equally efﬁcient at inducing transgene-speciﬁc tole-
rance, and this suggests that the pattern of transgene
expression (and not the level) plays a crucial role in
directing the immune system response in this setting.
A broad application of hepatocyte-targeted expression
by ICLVs for immune modulation is currently limited
by the concerns associated with integration in the target
cell genome. IDLVs are advantageous for this purpose
and could be exploited in inverse vaccination strategies
1706 MA ´TRAI ET AL. HEPATOLOGY, May 2011to tolerize individuals to protein replacement or gene
therapies and prevent the development of autoimmune
disease in at-risk individuals.
33 The present study sets
the stage for further testing in preclinical models.
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